CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 17,018 enrolled
Drug / intervention
Tiotropium (Tio) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05402020
NCT05402020N/ACompleted
CompareCT.gov

Effectiveness of Maintenance Treatment With Tiotropium + Olodaterol in Comparison to Inhaled Corticosteroids + Long-acting β2 Agonists in COPD Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

Boehringer Ingelheim·observational·Posted Jun 2, 2022·Updated Aug 9, 2024

In Brief

An observational study evaluating Tiotropium (Tio), Inhaled corticosteroids (ICS), and 2 other interventions for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 17,018 participants across 1 site.

Detailed Summary

The real world study aims to assess effectiveness and safety profile between tiotropium/olodaterol (Tio/Olo) and inhaled corticosteroids(ICS) / Long-acting β2-agonists (LABA) in patients with chronic obstructive pulmonary disease (COPD) in Taiwan. The data used in this study will come from the Taiwan National Health Insurance (NHI) claims data between 2014 and 2019.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedJun 2, 2022
Enrollment StartSep 30, 2022
Primary CompletionFeb 13, 2023
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 4.1 years ago

Interventions

Tiotropium (Tio)drug

Tiotropium (Tio)

Inhaled corticosteroids (ICS)drug

Inhaled corticosteroids (ICS)

Olodaterol (Olo)drug

Olodaterol (Olo)

Long-acting β2-agonists (LABA)drug

Long-acting β2-agonists (LABA)